Last Updated: August 3, 2026

Litigation Details for Uniloc 2017 LLC v. Google LLC (N.D. Cal. 2020)


✉ Email this page to a colleague

« Back to Dashboard


Uniloc 2017 LLC v. Google LLC (N.D. Cal. 2020)

Docket 4:20-cv-04355 Date Filed 2020-06-30
Court District Court, N.D. California Date Terminated 2023-03-08
Cause 35:271 Patent Infringement Assigned To Yvonne Gonzalez Rogers
Jury Demand Plaintiff Referred To Sallie Kim
Parties UNILOC USA, INC.
Patents 10,086,047; 12,398,102
Attorneys Aaron Seth Jacobs
Firms Perkins Coie LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Uniloc 2017 LLC v. Google LLC
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation summary and analysis for: Uniloc 2017 LLC v. Google LLC (N.D. Cal. 2020)

Last updated: July 25, 2026

Uniloc 2017 LLC v. Google LLC (E.D. Tex. 4:20-cv-04355): Litigation Summary, Posture, and Patent-Strength Analysis

Uniloc 2017 LLC v. Google LLC (E.D. Tex., No. 4:20-cv-04355) is a patent-infringement case targeting Google products that Uniloc alleges infringe Uniloc’s asserted patent(s). Public docket information is required to compile a complete, accurate litigation timeline (pleadings, claim construction, rulings, and trial posture) and an evidence-based infringement and validity analysis.

No further actionable litigation summary can be produced from the information provided.

What is the procedural status of Uniloc 2017 LLC v. Google LLC (4:20-cv-04355)?

A litigation status summary requires docket events (complaint filing date, service, answers/motions, scheduling order milestones, claim construction deadlines, Daubert or summary judgment filings, and any trial date orders). None of those inputs are present here, so the case posture cannot be stated accurately.

Which court handled the case and what is the case type?

  • Court: Eastern District of Texas (E.D. Tex.)
  • Case number: 4:20-cv-04355
  • Type: Patent infringement (implied by the party names and caption), but the asserted claims and asserted patents are not provided.

What did Uniloc and Google file and when?

A precise filing chronology (complaint, amended complaint, answer, infringement contentions, invalidity contentions, claim construction briefing, summary judgment and motions in limine) is not available in the prompt, so it cannot be summarized without generating errors.


What patents are asserted in Uniloc 2017 LLC v. Google LLC (4:20-cv-04355)?

An accurate patent-strength and litigation analysis must identify:

  • asserted patent number(s),
  • assignee(s) and inventorship,
  • representative independent claims,
  • infringement theory by product feature,
  • priority and prosecution history.

No asserted patent information is included, so the analysis cannot be completed.

How many patents cover Google in this case?

Cannot be determined without the asserted-patent list.

Who is the patent holder and what is the chain of title?

Cannot be determined without the patent metadata.


What is the infringement theory for Google in Uniloc 2017 LLC v. Google LLC?

A litigation infringement analysis requires mapping from claim limitations to accused functionalities (for example, advertising workflows, licensing APIs, device authentication, network communications, storage or encoding, or other technical elements), plus Uniloc’s infringement contentions and expert reports. Those specifics are not provided.

Which Google products or services are accused?

Not stated in the prompt.

What claim limitations does Uniloc allege are met?

Not stated in the prompt.


What invalidity defenses did Google raise against Uniloc’s asserted patents?

A real invalidity analysis needs the grounds asserted and the event history:

  • anticipation and obviousness references,
  • indefiniteness or written-description issues,
  • prosecution-history estoppel and claim scope limits,
  • noninfringement positions tied to claim construction.

No invalidity grounds are provided.

Did Google file IPR petitions at the PTAB related to the asserted patents?

PTAB filing status cannot be determined without the patent numbers and docket/public PTAB references.


What claim construction rulings affect Uniloc’s claims in this case?

Claim construction outcomes often drive settlement and dispositive motions. But without the Markman hearing date, the claim terms construed, and the court’s orders, the construction cannot be summarized.

Did the court construe key terms in Uniloc’s favor?

Cannot be answered without claim construction orders.

Did construction narrow asserted claims enough to defeat infringement?

Cannot be determined without construction and infringement mapping.


What motions resolved in Uniloc 2017 LLC v. Google LLC (4:20-cv-04355)?

Motion practice must be read off the docket: motions to dismiss, to strike, summary judgment, Daubert challenges, and any renewed dispositive motions.

No docket events are included.

Was there summary judgment or a partial summary judgment?

Cannot be determined.

Did the court address venue, personal jurisdiction, or transfer?

Cannot be determined.


What settlement or licensing outcome is reflected in the docket for Uniloc 2017 LLC v. Google LLC?

Settlement posture must be supported by docket entries such as dismissal without prejudice, stipulations, consent judgments, or confidentiality-related docket markings. None are provided.

Did the case end in dismissal, consent judgment, or ongoing litigation?

Cannot be determined.

Was there a stay pending PTAB proceedings?

Cannot be determined.


What is the Orange Book status of Uniloc’s asserted patents for Google (if any)?

Uniloc cases generally involve utility patents and do not track Orange Book listed drug exclusivities. Still, an “Orange Book status” section requires:

  • whether the case is about a drug,
  • whether any asserted patents are listed in the FDA Orange Book.

No asserted-patent or drug association is provided.


What is the competitive and commercial exposure for Google if Uniloc wins?

Commercial exposure needs:

  • accused product revenue lines,
  • damages theories (reasonable royalty basis, entire market value rule arguments),
  • comparable licenses,
  • injunctive relief risk and importation footprint.

No asserted patents or damages contentions are provided.


How does Uniloc’s patent estate strength compare to common challenges in E.D. Texas software/IP cases?

A credible strength analysis is claim-specific and evidence-based, using:

  • claim scope breadth from construction,
  • novelty over prior art,
  • dependence on functional/nonce claim terms,
  • litigation track record for the same patents,
  • proportionality of asserted claims to the accused features.

No patent numbers, claim chart, or prior art references are provided.


Key Takeaways

  • The prompt provides the case caption and docket number but not the asserted patent(s), accused products, docket events, claim construction, or dispositive rulings.
  • Without those inputs, a complete and accurate litigation summary and analysis cannot be produced without fabricating facts.

FAQs

  1. What is the earliest docket event for Uniloc 2017 LLC v. Google LLC (4:20-cv-04355)?
  2. Which Google products are accused in Uniloc 2017 LLC v. Google LLC?
  3. What claim construction terms most affected Uniloc’s infringement case?
  4. Did Google challenge the asserted patents via PTAB IPRs related to this case?
  5. What damages model did Uniloc propose (reasonable royalty vs. lost profits) in 4:20-cv-04355?

References

None provided.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.